Skip directly to content

Apply

Applicants

To be eligible for an investigator award, applicants must have a professional degree MD, PhD, PharmD or equivalent.

Deadline for Application and Key dates

  • Application Deadline: 31st August 2017
  • Award Announcement: October 2017
  • Project Start Date: July 2018
  • Project Duration: ≤18 months

How to Apply

Applications are to be submitted to Pfizer through an online submission website. Please click on the link below to be routed to Pfizer’s investigator-initiated research website. Click on “Submit an IIR Request” and follow the online instructions. If this is your first time visiting the portal you must first “Create an Account”. Begin the application form by selecting “yes” when asked if the submission is part of a competitive grant programme, then select the appropriate programme name ASPIRE haemophilia Europe.

Completed submissions must be accompanied by the following documents:

  • Cover letter on institution letterhead
  • 3 of the most relevant articles from the applicant’s scientific publications (if applicable)
  • Abbreviated curriculum vitae (CV) (limited to 3 pages)
  • Bibliography of relevant references
  • Budget for proposed research
  • Finalised protocol
    • The length of the text should be limited to a maximum of 3000 words including references and tables.
    • The proposed structure of the proposal is as follows:
      • Title
      • Background
      • Objective
      • Study design
      • Subject population
      • Primary and Secondary Efficacy Endpoints
      • Inclusion Criteria
      • Exclusion Criteria
      • Study procedures
      • Safety Endpoints
      • Statistical Considerations
      • Institutional Review Board (IRB) or Independent Ethics Committee (IEC) approval
      • Informed Consent and Privacy Authorisation
      • Description of Requested Support

    Application Process

    For online submission instructions click here

    To apply for a EUROPE ASPIRE 2017 award click here

    Questions

    Coordinator e-mail address: questions.europeaspire@pfizer.com

May 2017

PP-REF-EUR-0438